

1                   **Title: Mutual Potentiation of Plant Immunity by Cell-surface and**  
2   **Intracellular Receptors**

3   **Authors: Bruno Pok Man Ngou<sup>1</sup>, Hee-Kyung Ahn<sup>1</sup>, Pingtao Ding<sup>1,2\*</sup>, Jonathan DG Jones<sup>1\*</sup>**

4   **Affiliations:**

5   <sup>1</sup> The Sainsbury Laboratory, University of East Anglia, Norwich Research Park, Norwich NR4  
6   7UH, UK

7   <sup>2</sup> Current address: Institute of Biology Leiden, Leiden University, Sylviusweg 72, Leiden 2333  
8   BE, The Netherlands

9   \* Correspondence to: [p.ding@biology.leidenuniv.nl](mailto:p.ding@biology.leidenuniv.nl); [jonathan.jones@tsl.ac.uk](mailto:jonathan.jones@tsl.ac.uk)

10   **The plant immune system involves cell-surface receptors that detect intercellular pathogen-**  
11   **derived molecules, and intracellular receptors that activate immunity upon detection of**  
12   **pathogen-secreted effectors that act inside the plant cell. Surface receptor-mediated**  
13   **immunity has been extensively studied<sup>1</sup>, but intracellular receptor-mediated immunity has**  
14   **rarely been investigated in the absence of surface receptor-mediated immunity.**  
15   **Furthermore, interactions between these two immune pathways are poorly understood. By**  
16   **activating intracellular receptors in the absence of surface receptor-mediated immunity, we**  
17   **dissected interactions between the two distinct immune systems. Recognition by surface**  
18   **receptors activates multiple protein kinases and NADPH oxidases; we find intracellular**  
19   **receptors primarily potentiate the activation of these proteins by elevating their abundance**  
20   **via multiple mechanisms. Reciprocally, the intracellular receptor-dependent hypersensitive**  
21   **response is strongly enhanced by activation of surface receptors. Activation of either immune**  
22   **system alone is insufficient to provide effective resistance against the bacterial pathogen**  
23   ***Pseudomonas syringae*. Thus, immune pathways activated by cell-surface and intracellular**  
24   **receptors mutually potentiate to activate strong defense that thwarts pathogens. These**

25 **findings reshape our understanding of plant immunity and have broad implications for crop**  
26 **improvement.**

### 27 **Main Text**

28 Plant cell-surface pattern-recognition receptors (PRRs) recognize pathogen-associated molecular  
29 patterns (PAMPs) and signal *via* plasma-membrane-associated co-receptor kinases, and  
30 intracellular protein kinases<sup>1</sup>. Ligand-dependent association between PRRs and these protein  
31 kinases activates calcium influx, production of reactive oxygen species (ROS) via activation of  
32 NADPH oxidases encoded by respiratory burst oxidase homolog (Rboh) genes, activation of  
33 mitogen-activated protein kinases (MAPKs) and induction of defense genes<sup>1</sup>.

34 Intracellular nucleotide-binding, leucine-rich-repeat-containing (NLR) receptors activate immune  
35 responses upon recognition of pathogen effectors. Plant sensor NLRs carry either an N-terminal  
36 coiled-coil (CC) domain, or an N-terminal Toll/Interleukin-1 receptor/Resistance protein (TIR)  
37 domain<sup>2,3</sup>. Upon activation, the CC-NLR ZAR1 forms pentameric resistosome complexes,  
38 associates with plasma membranes (PMs) and likely perturbs their integrity<sup>4</sup>. The TIR-NLRs Roq1  
39 and RPP1 form tetrameric resistosomes with effectors XopQ and ATR1, respectively<sup>5,6</sup>. Upon  
40 activation, plant TIR-NLRs require NADase activity of their TIR domains to activate defense<sup>7</sup>.  
41 TIR-NLR signaling involves the lipase-like proteins EDS1, SAG101 and PAD4<sup>8</sup>. PRRs activate  
42 pattern-triggered immunity (PTI), and NLRs effector-triggered immunity (ETI)<sup>9</sup>. How PTI and  
43 ETI interact to arrest pathogens is poorly understood.

### 44 **ETI enhances PTI defense responses**

45 To study ETI without PTI, we generated an *Arabidopsis thaliana* (*Arabidopsis*) line with estradiol-  
46 inducible expression of bacterial effector AvrRps4 recognized by an intracellular TIR-NLR pair,  
47 RRS1 and RPS4 (RRS1/RPS4). Estradiol induces AvrRps4 expression and activates ETI<sup>AvrRps4</sup>.  
48 Pre-activation of ETI<sup>AvrRps4</sup> elevates plant resistance against *Pseudomonas syringae* pv. *tomato*  
49 (*Pst*) DC3000<sup>10</sup>. To test if ETI<sup>AvrRps4</sup> potentiates PTI, we measured ROS production triggered by  
50 flagellin-derived peptide flg22 (a bacterial PAMP) after pre-activating ETI<sup>AvrRps4</sup>. ETI<sup>AvrRps4</sup> pre-  
51 activation elevates ROS production induced by flg22, but induction of ETI<sup>AvrRps4</sup> alone does not  
52 activate ROS production (Extended Fig 1a-b). Estradiol pre-treatment in an *eds1-2* mutant

53 background does not elevate flg22-induced ROS (Extended Fig 1c-d). Thus, ETI<sup>AvrRps4</sup> enhances,  
54 but does not initiate, PTI.

55 During bacterial infection, PTI activation precedes effector delivery. To mimic this, we treated  
56 plants with flg22, or estradiol, or “flg22 + estradiol”, to activate PTI, or ETI<sup>AvrRps4</sup> or “PTI +  
57 ETI<sup>AvrRps4</sup>”. Over 16 hours (h), “PTI + ETI<sup>AvrRps4</sup>” shows elevated ROS compared to PTI alone,  
58 particularly during Phase III of the burst (Fig 1a, b and Extended Fig 1e, f). ETI<sup>AvrRps4</sup> enhances  
59 ROS production triggered by other PAMPs (elf18, C10:0, nlp20 and chitin) and the DAMP pep1  
60 (Extended Fig 2). We investigated if ETI mediated by CC-NLRs also potentiates PTI. The CC-  
61 NLR RPS2 recognizes bacterial effector AvrRpt2<sup>9</sup>. We found ETI<sup>AvrRpt2</sup> also elevates flg22-  
62 induced ROS (Extended Fig 1h-j). Thus, ETI activated by both TIR- or CC-NLRs can enhance  
63 ROS induced by PAMPs.

64 As “PTI + ETI” enhances the ROS burst of PTI alone, we assessed hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)  
65 levels in leaves after activation of PTI, ETI<sup>AvrRps4</sup> and “PTI + ETI<sup>AvrRps4</sup>”. The non-virulent *Pst*  
66 DC3000 *hrcC* mutant (*hrcC*<sup>-</sup>) induces PTI. Using diaminobenzidine (DAB) staining, “PTI +  
67 ETI<sup>AvrRps4</sup>”, but not PTI or ETI<sup>AvrRps4</sup> alone, trigger strong H<sub>2</sub>O<sub>2</sub> accumulation after 2 days (Fig 1c).  
68 H<sub>2</sub>O<sub>2</sub> promotes peroxidase-mediated cross-linking of proteins and phenolics in callose cell wall  
69 appositions during PTI<sup>11</sup>. ETI<sup>AvrRps4</sup> alone induces some callose deposition (Fig 1d). Callose  
70 deposition upon co-activation of PTI and ETI<sup>AvrRps4</sup> (“PTI + ETI<sup>AvrRps4</sup>”) is significantly higher  
71 than the sum of that induced by PTI and ETI<sup>AvrRps4</sup> alone (Fig 1d-e). Thus, PTI and ETI together  
72 enhance callose deposition. Furthermore, the expression of PTI-responsive genes such as *FRK1*,  
73 *NHL10*, *FOX1* is significantly higher 24 h after “PTI + ETI<sup>AvrRps4</sup>” treatment compared to PTI or  
74 ETI<sup>AvrRps4</sup> alone (Fig 1f and Extended Fig 1g). In summary, PTI-induced physiological changes  
75 are potentiated and enhanced by ETI.

76 Upon PAMP recognition, phosphorylation of the receptor-like cytoplasmic kinase subfamily VII  
77 (RLCK-VII) member BIK1 activates the NADPH oxidase RbohD *via* phosphorylation at its 39<sup>th</sup>  
78 and 343<sup>rd</sup> serine residues (S39 and S343). Activated RbohD produces extracellular ROS<sup>12,13</sup>. PTI  
79 also activates MAPKs, such as MPK3 and MPK6, contributing to transcriptional reprogramming  
80 (Extended Fig 3a)<sup>14</sup>. We compared the activation of BIK1, RbohD and MAPKs during PTI and  
81 “PTI + ETI<sup>AvrRps4</sup>”. Both pre-activation and co-activation of ETI<sup>AvrRps4</sup> result in prolonged flg22-

82 induced phosphorylation of BIK1, RbohD (at S39 and S343) and MPK3 (Figure 2a, b, Extended  
83 Fig 3b-e). However, ETI<sup>AvrRps4</sup> activation alone does not lead to phosphorylation of RbohD and  
84 MAPKs (Figure 2c, d)<sup>10</sup>. To investigate how ETI potentiates PTI, we monitored accumulation of  
85 BIK1, RbohD and MPK3 proteins during “PTI + ETI<sup>AvrRps4</sup>” compared to PTI alone (Figure 2a, b  
86 and Extended Fig 3d, e). More of these proteins accumulate during “PTI + ETI<sup>AvrRps4</sup>” than during  
87 PTI alone. We assessed protein levels of multiple PTI signaling components during ETI activated  
88 in four additional inducible effector-expressing lines: AvrRpp4, AvrRpt2, AvrRpm1 and AvrPphB,  
89 which are recognized by TIR-NLR RPP4 and CC-NLRs RPS2, RPM1 and RPS5, respectively  
90 (Extended Fig 3f)<sup>15</sup>. ETI triggered by these effectors elevates protein accumulation of BAK1,  
91 SOBIR1, BIK1, RbohD and MPK3 but not CERK1, FLS2, MPK4 and MPK6 (Extended Fig 3g).

92 Transcription and translation are strongly correlated during ETI<sup>16</sup>. We tested if PTI signaling  
93 components are elevated by transcriptional induction. ETI triggered by different effectors strongly  
94 elevates transcript abundance of *BAK1*, *SOBIR1*, *BIK1*, *RbohD* and *MPK3*, and weakly that of  
95 *CERK1*, *FLS2*, *RbohF*, *MPK4* and *MPK6* (Extended Fig 4a, b). Both protein and transcript  
96 accumulation of BIK1, RbohD and MPK3 during ETI<sup>AvrRps4</sup> is EDS1-dependent (Extended Fig 4c,  
97 d). Thus, ETI alone boosts transcription of many genes involved in PTI signaling. We performed  
98 genome-wide expression profiling 4 h after induction of ETI<sup>AvrRps4</sup> and found ~10% of the  
99 transcriptome shows significant differential gene expression (Extended Fig 5a, b). Most  
100 upregulated genes are enriched in immunity-related biological processes, especially PRR signaling  
101 pathways (Fig 2c, Extended Fig 5c-e). Additional PTI signaling components such as *EFR*,  
102 *PEPR1/2*, *LORE*, *LYK5*, *XLG2*, *CNGC19* and *MKK4/5* are highly upregulated during ETI<sup>AvrRps4</sup>.  
103 Thus, ETI-dependent gene induction elevates the abundance of PTI signaling components.

104 Previous studies suggest substantial overlap between PTI- and “PTI + ETI”-induced  
105 transcriptional reprogramming<sup>17,18</sup>. We tested if increases in PTI signaling components during ETI  
106 are solely due to transcriptional activation. Transcript and protein levels of several PTI signaling  
107 components were monitored over a 24-h time-course post ETI<sup>AvrRps4</sup>-induction (Fig 3a, b).  
108 Consistent with the protein level, *SOBIR1* and *BAK1* transcripts are highly induced by ETI<sup>AvrRps4</sup>  
109 (Fig 3a, b). However, *BIK1*, *RbohD* and *MPK3* mRNAs are upregulated briefly and then  
110 downregulated after 3 h, while increases in their protein levels are sustained over 24 h (Fig 3a, b  
111 and Extended Fig 6a-e). *CERK1*, *MPK4* and *MPK6* transcripts are weakly induced without

112 elevating protein abundance. In addition, ETI<sup>AvrRps4</sup> and “PTI + ETI<sup>AvrRps4</sup>” both lead to stronger  
113 BIK1, RbohD and MPK3 accumulation compared to PTI, but their transcript levels differ only  
114 slightly between different conditions (Extended Fig 6f). These results imply that increases in PTI-  
115 signaling components during ETI<sup>AvrRps4</sup> involves both transcriptional and post-transcriptional  
116 regulation.

117 We investigated accumulation of PTI-signaling components during ETI<sup>AvrRps4</sup> using the translation  
118 inhibitor cycloheximide (CHX) and/or a proteasome inhibitor MG132. CHX blocks the  
119 accumulation of BIK1, RbohD, MPK3 and BAK1 during ETI, but not MPK6 or Actin (Fig 3c and  
120 Extended Fig 7a, b). MG132 treatment results in higher accumulation of BIK1 and RbohD but has  
121 no effect on MPK3 or BAK1 (Fig 3c and Extended Fig 7a, b). MPK3 accumulation is similar  
122 between the combined treatment of CHX and MG132 (“CHX + MG132”) and CHX alone  
123 (Extended Fig 7b), suggesting that elevated MPK3 protein accumulation is likely due to increased  
124 translation rather than decreased protein degradation. BIK1 and RbohD protein levels increase  
125 with “CHX + MG132” treatment compared to those with CHX (Extended Fig 7b), implying that  
126 protein turnover of BIK1 and RbohD also plays a role<sup>19,20</sup>. However, this increase was not observed  
127 with FLS2, BAK1 or epitope-tagged RPS4 (Extended Fig 7c). Since translational reprogramming  
128 also contributes to immunity<sup>21</sup>, we compared abundance of ribosome-bound transcripts of *ICS1*,  
129 *SOBIR1*, *BAK1*, *BIK1*, *RbohD* and *MPK3*, normalized to a housekeeping gene *EF1α* during mock  
130 and ETI<sup>AvrRps4</sup> treatment (Extended Fig 7d-f). ETI-induced increases in mRNA levels for *BIK1*,  
131 *RbohD* and *MPK3* are matched by elevation in ribosome-loaded mRNA levels (Extended Fig 7g-  
132 h). ETI thus elevates protein levels of PTI signaling components via multiple and distinct  
133 mechanisms that will be the subject of future investigations.

### 134 **ETI functions through PTI**

135 Whether ETI and PTI activate the same or distinct mechanisms is poorly defined, because ETI  
136 responses are rarely investigated in the absence of PTI. We tested whether (i) PTI provides the  
137 main defense mechanism against pathogens and (ii) ETI enhances PTI by replenishing PTI  
138 components, thus restoring effector-attenuated PTI.

139 We challenged plants with non-virulent *Pst* DC3000 *hrcC*<sup>-</sup> and found protein levels of BIK1 and  
140 RbohD are slightly elevated during PTI, and MAPKs are activated and show elevated

141 phosphorylation. After infiltration with a virulent strain *Pst* DC3000, PTI-induced protein  
142 accumulation of BIK1 and RbohD, and MAPK activation is reduced compared to *hrcC*<sup>-</sup>, consistent  
143 with effector-triggered susceptibility (ETS)<sup>9</sup>. We co-infiltrated plants with DC3000 and estradiol  
144 to co-induce ETI<sup>AvrRps4</sup> which restored protein levels of BIK1, RbohD and MPK3 and prolonged  
145 activation of MAPKs (Extended Fig 8a). This indicates that ETI overcomes ETS and restores PTI  
146 signaling capacity.

147 During natural infections, ETI is rarely activated without PTI. We hypothesized that ETI provides  
148 robust resistance by restoring and elevating the abundance of PTI signaling components,  
149 compensating for their turnover upon activation and attenuation by ETS (Extended Fig 8b). This  
150 model implies NLR-mediated resistance functions through PTI. We tested if PTI is required for  
151 NLR-dependent ETI-enhanced disease resistance by infiltrating the PTI-compromised mutants  
152 *bak1-5 bkk1-1* and *fls2 efr* with *Pst* DC3000 delivering AvrRps4 (DC3000:AvrRps4)<sup>22</sup>.  
153 Remarkably, *bak1-5 bkk1-1* is as susceptible as the NLR mutant *rps4-2 rps4b-2* that cannot detect  
154 AvrRps4 (Figure 4a and Extended Fig 8c), while *fls2 efr* also showed enhanced susceptibility to  
155 DC3000:AvrRps4 compared to wild type (Extended Fig 8d-g). These data show that PTI is  
156 required for *RRS1/RPS4*-dependent resistance to bacteria, and that activation of ETI in the absence  
157 of PTI is not sufficient for enhanced resistance against *P. syringae* in Arabidopsis. In addition,  
158 Yuan *et al* (co-submitted manuscript, 2020-04-06411) provide complementary data, independently  
159 showing that PTI is required for induced bacterial resistance mediated by multiple NLRs.

### 160 **PTI potentiates ETI-induced cell death**

161 ETI in the presence of PTI often culminates in hypersensitive cell death responses (HR).  
162 Arabidopsis infiltration with a non-pathogenic *P. fluorescens* Pf0-1 delivering AvrRps4 (Pf0-  
163 1:AvrRps4<sup>WT</sup>) triggers “PTI + ETI<sup>AvrRps4</sup>” and HR. However, ETI<sup>AvrRps4</sup> alone does not lead to HR  
164 (Extended Fig 9a)<sup>10</sup>. We used a Pf0-1 strain delivering a mutant allele of AvrRps4 (Pf0-  
165 1:AvrRps4<sup>mut</sup>) to activate PTI. Co-activation of PTI and ETI<sup>AvrRps4</sup> results in HR and elevated  
166 electrolyte leakage (a widely used indicator of cell death), unlike PTI or ETI<sup>AvrRps4</sup> alone (Extended  
167 Fig 9a, b). To test if other PTI-inducers also potentiate HR, we repeated the experiment with either  
168 *hrcC*<sup>-</sup> strain Pf0-1, a mixture of PAMPs and a DAMP (flg22, elf18 and pep1), or PAMPs or a  
169 DAMP alone (flg22, elf18, pep1, C10:0, nlp20 or chitin) to activate PTI<sup>1</sup>. In all cases, only PAMP

170 infiltration combined with ETI<sup>AvrRps4</sup> triggers HR (Figure 4b and Extended Fig 9c). Thus, PTI  
171 potentiates ETI-induced HR.

172 Like “PTI + ETI<sup>AvrRps4</sup>”, co-activation of PTI and ETI<sup>AvrRpp4</sup> causes HR, but not PTI or ETI<sup>AvrRpp4</sup>  
173 alone (Extended Fig 9e). In contrast, inducible expression of AvrRpt2, AvrRpm1 and AvrPphB  
174 that are recognized by CC-NLRs can trigger HR in the absence of PTI (Extended Fig 9d). By  
175 reducing levels of estradiol or dexamethasone, we defined sub-lethal levels of AvrRpt2, AvrRpm1  
176 and AvrPphB induction. At these levels, CC-NLR mediated HR was also enhanced by PTI co-  
177 activation (Extended Fig 9e). Thus, PTI activation enhances HR triggered by multiple NLRs.

178 MAPKs and Rboh proteins promote ETI-dependent HR<sup>23,24</sup>. To understand PTI-enhanced ETI-  
179 associated HR, we investigated the role of MAPKs and Rbohs during ETI alone. We found  
180 MAPKs are phosphorylated during ETI<sup>AvrRpm1</sup>, ETI<sup>AvrRpt2</sup> and ETI<sup>AvrPphB</sup>, but not during ETI<sup>AvrRps4</sup>  
181 or ETI<sup>AvrRpp4</sup> (Fig 2c and Extended Fig 10a). However, none of the inducible ETIs led to RbohD  
182 phosphorylation at S39 (Extended Fig 10b). ETI<sup>AvrRpt2</sup> leads to RbohD phosphorylation at S343  
183 and S347<sup>25</sup>, which might explain why ETI<sup>AvrRpt2</sup> activates a weak ROS burst (Extended Fig 1h-j).

184 Since ETI potentiates PTI-induced activation of MPK3 and RbohD, and ETI alone leads to weak  
185 or no activation of these components, we tested if HR enhancement by PTI involves the ETI-  
186 potentiated activity of MAPKs and NADPH oxidases. In an Arabidopsis line *MPK6SR*, an *mpk3*  
187 *mpk6* double mutant is complemented by a mutant MPK6 allele (MPK6<sup>YG</sup>)<sup>26</sup>. Activity of MPK6<sup>YG</sup>  
188 but not the wild-type MPK6 can be inhibited by an ATP analogue 1-NA-PP1<sup>26</sup>. We tested the  
189 response to Pf0-1:AvrRps4<sup>WT</sup> (“PTI + ETI<sup>AvrRps4</sup>”) in the *MPK6SR* line in the presence or absence  
190 of 1-NA-PP1. Like others<sup>23</sup>, we found inhibition of MPK6<sup>YG</sup> in *MPK6SR* prevents ETI<sup>AvrRps4</sup>-  
191 associated HR even in the presence of PTI (Extended Fig 10c). Furthermore, HR induced by Pf0-  
192 1:AvrRps4<sup>WT</sup> is reduced in the NADPH oxidase mutant *rbohD rbohF* (Extended Fig 10d). Together,  
193 these results demonstrate that the activation of MAPK and NADPH oxidases during “PTI +  
194 ETI<sup>AvrRps4</sup>” contributes to HR.

## 195 Discussion

196 We show here that ETI requires PTI to provide effective resistance. PTI can halt pathogens through  
197 nutrient restriction, cell wall fortification, suppression of bacterial type III secretion and induction  
198 of antimicrobial compounds<sup>11,27,28</sup>. ETI enhances PTI-induced defense responses *via* upregulation

199 of PTI signaling components, and transcriptional, translational and/or protein turnover control  
200 (Extended Fig 10e). How this is achieved for each PTI component remains to be determined. We  
201 also show that the stronger immune response during “PTI + ETI” involves mutual potentiation of  
202 these two systems.

203 Our data, and those of Yuan *et al* (~~co-submitted manuscript, 2020-04-06411~~), support a model in  
204 which defenses activated by PRR-dependent signaling are the primary source of immunity, and  
205 activated NLR receptors act to replenish PRR signaling components and enhance PRR-dependent  
206 signaling, counteracting attenuation by turnover upon activation and by pathogen effectors (Fig  
207 4c). In turn, PRR-mediated immunity can potentiate ETI outputs such as HR to further restrict  
208 pathogen proliferation. These data are highly relevant to elevating crop disease resistance. Many  
209 *NLR* genes are semi-dominant, suggesting ETI strength is rate-limiting for resistance<sup>29</sup>. Thus, when  
210 PTI is present, stacks of multiple *NLR* genes should provide physiologically stronger resistance,  
211 as well as enhancing genetic durability, and are a potential source of non-host resistance<sup>30</sup>. Other  
212 reports have indicated synergistic functions of cell-surface and intracellular receptors in  
213 mammalian immunity<sup>31,32</sup>, highlighting the relevance of these insights to multiple host-pathogen  
214 systems.

## 215 **References**

- 216 1. Couto, D. & Zipfel, C. Regulation of pattern recognition receptor signalling in plants. *Nat.*  
217 *Rev. Immunol.* **16**, 537–552 (2016).
- 218 2. Jones, J. D. G., Vance, R. E. & Dangl, J. L. Intracellular innate immune surveillance devices  
219 in plants and animals. *Science* **354**, (2016).
- 220 3. Monteiro, F. & Nishimura, M. T. Structural, functional, and genomic diversity of plant NLR  
221 proteins: an evolved resource for rational engineering of plant immunity. *Annu. Rev.*  
222 *Phytopathol.* **56**, 243–267 (2018).
- 223 4. Wang, J. *et al.* Reconstitution and structure of a plant NLR resistosome conferring immunity.  
224 *Science* **364**, (2019).
- 225 5. Martin, R. *et al.* Structure of the activated ROQ1 resistosome directly recognizing the  
226 pathogen effector XopQ. *Science* **370**, eabd9993 (2020).
- 227 6. Ma, S. *et al.* Direct pathogen-induced assembly of an NLR immune receptor complex to form  
228 a holoenzyme. *Science* **370**, eabe3069 (2020).



- 229 7. Duxbury, Z., Wu, C. & Ding, P. A Comparative Overview of the Intracellular Guardians of  
230 Plants and Animals: NLRs in Innate Immunity and Beyond. *Annu. Rev. Plant Biol.* (2021). at  
231 <<https://doi.org/10.1146/annurev-arplant-080620-104948>>
- 232 8. Lapin, D. *et al.* A Coevolved EDS1-SAG101-NRG1 Module Mediates Cell Death Signaling  
233 by TIR-Domain Immune Receptors. *Plant Cell* **31**, 2430–2455 (2019).
- 234 9. Jones, J. D. G. & Dangl, J. L. The plant immune system. *Nature* **444**, 323–329 (2006).
- 235 10. Ngou, B. P. M. *et al.* Estradiol-inducible AvrRps4 expression reveals distinct properties of  
236 TIR-NLR-mediated effector-triggered immunity. *J. Exp. Bot.* **71**, 2186–2197 (2020).
- 237 11. Voigt, C. A. Callose-mediated resistance to pathogenic intruders in plant defense-related  
238 papillae. *Front. Plant Sci.* **5**, 168 (2014).
- 239 12. Kadota, Y. *et al.* Direct regulation of the NADPH oxidase RBOHD by the PRR-associated  
240 kinase BIK1 during plant immunity. *Mol. Cell* **54**, 43–55 (2014).
- 241 13. Li, L. *et al.* The FLS2-associated kinase BIK1 directly phosphorylates the NADPH oxidase  
242 RbohD to control plant immunity. *Cell Host Microbe* **15**, 329–338 (2014).
- 243 14. Meng, X. & Zhang, S. MAPK cascades in plant disease resistance signaling. *Annu. Rev.*  
244 *Phytopathol.* **51**, 245–266 (2013).
- 245 15. Kourelis, J. & van der Hoorn, R. A. L. Defended to the nines: 25 years of resistance gene  
246 cloning identifies nine mechanisms for R protein function. *Plant Cell* **30**, 285–299 (2018).
- 247 16. Metegnier, L.-V. *et al.* Translatome analysis of an NB-LRR immune response identifies  
248 important contributors to plant immunity in Arabidopsis. *J. Exp. Bot.* **68**, 2333–2344 (2017).
- 249 17. Ding, P. *et al.* High-resolution expression profiling of selected gene sets during plant immune  
250 activation. *Plant Biotechnol. J.* (2020). doi:10.1111/pbi.13327
- 251 18. Ding, P. *et al.* Chromatin accessibility landscapes activated by cell surface and intracellular  
252 immune receptors. *BioRxiv* (2020). doi:10.1101/2020.06.17.157040
- 253 19. Ma, X. *et al.* Ligand-induced monoubiquitination of BIK1 regulates plant immunity. *Nature*  
254 **581**, 199–203 (2020).
- 255 20. Lee, D. *et al.* Regulation of reactive oxygen species during plant immunity through  
256 phosphorylation and ubiquitination of RBOHD. *Nat. Commun.* **11**, 1838 (2020).
- 257 21. Urquidi Camacho, R. A., Lokdarshi, A. & von Arnim, A. G. Translational gene regulation in  
258 plants: A green new deal. *Wiley Interdiscip Rev RNA* **11**, e1597 (2020).

- 259 22. Roux, M. *et al.* The *Arabidopsis* leucine-rich repeat receptor-like kinases BAK1/SERK3 and  
260 BKK1/SERK4 are required for innate immunity to hemibiotrophic and biotrophic pathogens.  
261 *Plant Cell* **23**, 2440–2455 (2011).
- 262 23. Su, J. *et al.* Active photosynthetic inhibition mediated by MPK3/MPK6 is critical to effector-  
263 triggered immunity. *PLoS Biol.* **16**, e2004122 (2018).
- 264 24. Torres, M. A., Dangl, J. L. & Jones, J. D. G. *Arabidopsis* gp91phox homologues AtrbohD and  
265 AtrbohF are required for accumulation of reactive oxygen intermediates in the plant defense  
266 response. *Proc. Natl. Acad. Sci. USA* **99**, 517–522 (2002).
- 267 25. Kadota, Y. *et al.* Quantitative phosphoproteomic analysis reveals common regulatory  
268 mechanisms between effector- and PAMP-triggered immunity in plants. *New Phytol.* **221**,  
269 2160–2175 (2019).
- 270 26. Xu, J. *et al.* A chemical genetic approach demonstrates that MPK3/MPK6 activation and  
271 NADPH oxidase-mediated oxidative burst are two independent signaling events in plant  
272 immunity. *Plant J.* **77**, 222–234 (2014).
- 273 27. Yamada, K., Saijo, Y., Nakagami, H. & Takano, Y. Regulation of sugar transporter activity  
274 for antibacterial defense in *Arabidopsis*. *Science* **354**, 1427–1430 (2016).
- 275 28. Anderson, J. C. *et al.* Decreased abundance of type III secretion system-inducing signals in  
276 *Arabidopsis* *mkp1* enhances resistance against *Pseudomonas syringae*. *Proc. Natl. Acad. Sci.*  
277 *USA* **111**, 6846–6851 (2014).
- 278 29. Jones, J. D. Putting knowledge of plant disease resistance genes to work. *Curr. Opin. Plant*  
279 *Biol.* **4**, 281–287 (2001).
- 280 30. Cevik, V. *et al.* Transgressive segregation reveals mechanisms of *Arabidopsis* immunity to  
281 Brassica-infecting races of white rust (*Albugo candida*). *Proc. Natl. Acad. Sci. USA* **116**,  
282 2767–2773 (2019).
- 283 31. Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 inflammasome: an overview of  
284 mechanisms of activation and regulation. *Int. J. Mol. Sci.* **20**, (2019).
- 285 32. Wolf, A. J. & Underhill, D. M. Peptidoglycan recognition by the innate immune system. *Nat.*  
286 *Rev. Immunol.* **18**, 243–254 (2018).

287

288 **Fig. 1 | ETI potentiates PTI responses.** (a) “PTI + ETI<sup>AvrRps4</sup>” leads to prolonged ROS production  
289 from 300-960 mins (Phase III). Solid line represents mean  $\pm$  standard error of the mean (S.E.;  
290 shaded curve).  $n = 40$  leaf disks. (b) Total ROS production in “PTI + ETI<sup>AvrRps4</sup>”-treated leaves is  
291 significantly higher than PTI-treated leaves.  $n = 120$  leaf disks from three independent  
292 experiments. (c) “PTI + ETI<sup>AvrRps4</sup>” leads to higher H<sub>2</sub>O<sub>2</sub> accumulation than PTI or ETI<sup>AvrRps4</sup>  
293 alone. Scale bars represent 0.5 cm.  $n = 12$  leaves. (d) “PTI + ETI<sup>AvrRps4</sup>” leads to stronger callose  
294 deposition than PTI or ETI<sup>AvrRps4</sup> alone. Numbers represent the mean  $\pm$ S.E. (e) Callose deposition  
295 in “PTI + ETI<sup>AvrRps4</sup>”-treated leaves is higher than PTI- or ETI<sup>AvrRps4</sup>-treated leaves. Mock:  $n = 21$   
296 leaves; PTI, ETI, “PTI + ETI”:  $n = 23$  leaves. (b, e) Centre lines represent medians; bounds of box  
297 indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles; whiskers represent 1.5 $\times$  interquartile range from 25<sup>th</sup> and 75<sup>th</sup>  
298 percentiles. Data points from 3 biological replicates were analyzed with one-sided Kruskal-Wallis  
299 test with Holm correction, then followed by post hoc Dunn’s test. Data points with different letters  
300 indicate significant differences of  $P < 0.05$ . P-values were adjusted with Holm correction, and  
301 exact P-values can be found in Supplementary Table 5. (f) “PTI + ETI<sup>AvrRps4</sup>” leads to a stronger  
302 *FRK1*, *NHL10*, *FOX1* transcript accumulation compared to PTI or ETI<sup>AvrRps4</sup> alone. Data points  
303 from 3 independent experiments were plotted onto the graphs, with  $\pm$ S.E. for error bars. Two-sided  
304 Welch’s t-test was used to analyze significant differences between “PTI + ETI<sup>AvrRps4</sup>” and PTI or  
305 ETI<sup>AvrRps4</sup>. (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P \leq 0.001$ ; otherwise, not significant).  
306 Exact P-values can be found in Supplementary Table 5. All experiments were repeated at least  
307 three times with similar results.

308 **Fig. 2 | ETI potentiates activation of PTI signaling components.** (a) “PTI + ETI<sup>AvrRps4</sup>” co-  
309 activation leads to increased MPK3 accumulation and prolonged phosphorylation compared to  
310 PTI. (b) “PTI + ETI<sup>AvrRps4</sup>” co-activation leads to increased BIK1 and RbohD accumulation and  
311 prolonged phosphorylation compared to PTI. (c) ETI<sup>AvrRps4</sup> activation alone does not trigger  
312 RbohD-S39 phosphorylation. (d) ETI<sup>AvrRps4</sup> alone does not lead to MAPK activation. For (b, c),  
313 microsomal fractions from the samples were isolated for immunoblotting. Molecular weight  
314 marker (in kDa) is indicated on the left. Ponceau staining (PS) was used as loading control. (e)  
315 RNA-seq results of the upregulation of PTI signaling pathway during ETI<sup>AvrRps4</sup>. Heatmap  
316 representing the expression level of PTI signaling pathway genes, salicylic acid (SA) and piperolic  
317 acid (PIP) biosynthesis pathway genes and photosynthetic pathway genes at 4 h after ETI<sup>AvrRps4</sup>

318 induction. Red represents upregulation and blue represents downregulation. All experiments were  
319 repeated at least three times with similar results.

320 **Fig. 3 | Accumulation of PTI signaling components during ETI.** (a) Relative mRNA expression  
321 changes of *SOBIR1*, *BAK1* (top panel), *BIK1*, *RbohD*, *MPK3* (middle panel), and *CERK1*, *MPK4*,  
322 *MPK6* (bottom panel) upon ETI<sup>AvrRps4</sup> induction. Samples were taken at indicated time points after  
323 ETI<sup>AvrRps4</sup> activation. All samples were normalized against expression of the corresponding genes  
324 in untreated samples ( $\log_2FC = 0$ , dotted line). Solid line represents mean  $\pm$  S.E. (shaded band).  
325 (b) Protein accumulation of Actin, SOBIR1, BAK1, BAK1, RbohD, MPK3, CERK1, MPK4 and  
326 MPK6 at different time points; Actin is the loading control. Molecular weight is indicated on the  
327 left. Ponceau staining (PS) was used as additional loading control and shown in Extended Fig 6d.  
328 (c) Translation is necessary for the increased protein accumulation of MPK3, RbohD, BIK1, but  
329 not MPK6 and Actin. 7-day-old seedlings were pre-activated with ETI<sup>AvrRps4</sup> for 3 h and  
330 subsequently treated with cycloheximide (50  $\mu$ M; CHX), MG132 (10  $\mu$ M), or both for indicated  
331 times (2, 4, 8 h). Actin is loading control. Molecular weight (in kDa) is indicated on the left.  
332 Ponceau staining (PS) images of corresponding blots are also shown. All experiments were  
333 repeated at least three times with similar results.

334 **Fig. 4 | PTI and ETI function synergistically to provide robust immunity.** (a) Both PTI and  
335 ETI<sup>AvrRps4</sup> are required to provide effective immunity against *P. syringae*. Col-0, *rps4-2 rps4b-2*  
336 and *bak1-5 bkk1-1* were infected with *P. syringae* pv. *tomato* (*Pst*) strain DC3000 carrying empty  
337 vector (grey) or AvrRps4 (pink). Both *rps4-2 rps4b-2* (no ETI) and *bak1-5 bkk1-1* (PTI-reduced)  
338 are insufficient to provide resistance against *Pst* DC3000 carrying AvrRps4 compared to Col-0  
339 (“PTI + ETI”).  $n = 18$  leaves. Centre lines represent medians; bounds of box indicate the 25<sup>th</sup> and  
340 75<sup>th</sup> percentiles; whiskers represent 1.5 $\times$  interquartile range from 25<sup>th</sup> and 75<sup>th</sup> percentiles. Data  
341 points from 3 biological replicates were analyzed with one-way ANOVA, then followed by post  
342 hoc Tukey’s HSD test. Data points with different letters indicate significant differences of  $P <$   
343 0.05. P-values were adjusted with Holm correction, and exact P-values can be found in  
344 Supplementary Table 5. (b) ETI<sup>AvrRps4</sup> leads to macroscopic HR only in the presence of PTI,  
345 activated by either non-virulent *Pst* DC3000 *hrcC*, *P. fluorescens* Pf0-1 or mixture of flg22, elf18  
346 and pep1 (PAMPs).  $n = 18$  leaves. (c) Schematic representation of the plant immune system.  
347 PAMPs from pathogens are recognized by plant PRRs and induce PTI (red). Virulent pathogens

348 secrete effectors to suppress PTI (green). Effectors are recognized by NLRs and induce ETI (dark  
349 yellow arrow), which potentiates PTI to produce robust immune response (blue arrow). All  
350 experiments were repeated at least three times with similar results.

## 351 **Methods**

### 352 Plant material and growth conditions

353 *Arabidopsis thaliana* Columbia-0 (Col-0) was used as wild type in this study. Seeds were sown on  
354 compost and plants were grown at 21 °C with 10 h under light and 14 h in dark, and at 70%  
355 humidity. The light level is approximately 180-200  $\mu\text{mol}$  with fluorescent tubes. Information about  
356 all plant materials can be found in the referred literatures<sup>26,33-37</sup>, and were kindly provided by  
357 Jeffery Dangl (Department of Biology, The University of North Carolina at Chapel Hill), Roger  
358 Innes (Department of Biology, Indiana University), Shuta Asai (RIKEN, Japan), Shuqun Zhang  
359 (Division of Biochemistry, University of Missouri), Xiufang Xin (Shanghai Institutes for Biology  
360 Sciences, Chinese Academy of Sciences) and Cyril Zipfel (The Sainsbury Laboratory, UK).

### 361 ROS burst assay (pre-treatment with ETI)

362 Leaf discs harvested with a 6-mm-diameter cork borer from 5-week-old plants were placed in 96-  
363 well plates with 200  $\mu\text{l}$  of deionized water overnight in dark (with abaxial surface of the leaves  
364 face down). Leaf discs were then soaked in mock solution (1% DMSO) or 50  $\mu\text{M}$  est (estradiol to  
365 trigger ETI<sup>AvrRps4</sup>) for 6 h. 200  $\mu\text{l}$  of 20 mM luminol (Sigma-Aldrich, A8511), 0.02 mg/ml  
366 horseradish peroxidase (Sigma-Aldrich, P6782) and 100 nM flg22 were added in each well. ROS  
367 production was measured with a Photek camera (East Sussex, UK). Data from each treatment is  
368 represented by 40 leaf discs in one biological replicate. Every plate was measured over 55 mins.

### 369 ROS burst assay (co-treatment with ETI)

370 Leaf discs harvested with a 6-mm-diameter cork borer from 5-week-old plants were placed in 96-  
371 well plates with 200  $\mu\text{l}$  of deionized water overnight in dark (with abaxial surface of the leaves  
372 face down). 200  $\mu\text{l}$  of 20 mM luminol (Sigma-Aldrich, A8511), 0.02 mg/ml horseradish peroxidase  
373 (Sigma-Aldrich, P6782) and indicated elicitors (concentration indicated in Supplementary Table  
374 3) were added in each well. ROS production was measured with a Photek camera (East Sussex,  
375 UK). Data from each treatment is represented by 40 leaf discs in one biological replicate. Every  
376 plate was measured over the 16 h.

377  
378  
379  
380  
381  
382  
383  
384  
  
385  
386  
387  
388  
389  
390  
391  
392  
  
393  
394  
395  
396  
397  
398  
399  
400  
401  
  
402  
403  
404  
405

### DAB staining

3,3'-diaminobenzidine (Sigma-Aldrich, D8001) was dissolved in water (1 mg/ml) and the pH is adjusted to 6 with sodium hydroxide. Arabidopsis leaves were infiltrated with indicated solutions (concentration indicated in Supplementary Table 3). Two days after infiltration, leaves were vacuum infiltrated with DAB solution for 30 mins and incubated in room temperature for 2 h. The DAB solution was replaced with 100% ethanol and then boiled for 1 mins. The leaves are then further de-stained with 70% ethanol under room temperature. De-stained leaves were then scanned with EPSON Perfection V600 Photo. Scale bar = 0.5 cm.

### Callose quantification

Leaves from 5-week-old Arabidopsis were hand-infiltrated with the indicated solutions (concentration indicated in Supplementary Table 3) and covered for 24 h. Leaves were then hand-infiltrated with 1× PBS buffer containing 0.01% Aniline Blue. Leaf discs were then harvested with a 6-mm-diameter cork borer for imaging. Images were taken by an epifluorescence microscope with UV filter (excitation, 365/10 nm; emission, 460/50 nm). The number of callose dots was calculated by ImageJ software. One leaf disc was harvested per leaf. At least 6 leaves from individual plants were included per treatment in one biological replicate.

### Gene expression analysis by reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

*Arabidopsis thaliana* tissues were treated with indicated solutions (concentration indicated in Supplementary Table 3) for indicated time point. Tissues were then snap-frozen and RNA was isolated by RNeasy Plant Mini Kit (74904; Qiagen) and used for subsequent RT-qPCR analysis. Reverse transcription was carried out with SuperScript IV Reverse Transcriptase (18090050; ThermoFisher Scientific). qPCR was performed with KAPA SYBR® FAST (Roche) using the CFX96 Touch™ Real-Time PCR Detection System. Primers for qPCR analysis are listed in Supplementary Information Table 2. Data were analyzed using the double delta Ct method<sup>38</sup>.

### Immunoblotting (pre-treatment with ETI)

5-week-old Est:AvrRps4 leaves were sprayed with either mock or 50 µM est solution (in 0.01% Silwet L-77) and covered for 6 h. Leaves were then infiltrated with 100 nM flg22. Samples were collected at indicated time points and snap-frozen in liquid nitrogen. Samples were lysed and

406 proteins were extracted using GTEN buffer (10% glycerol, 25 mM Tris pH 7.5, 1 mM EDTA, 150  
407 mM NaCl) with 10 mM DTT, 1% NP-40 and protease inhibitor cocktail (cOmplete™, EDTA-free;  
408 Merck), phosphatase inhibitor cocktail 2 (Sigma-Aldrich; P5726) and phosphatase inhibitor  
409 cocktail 3 (Sigma-Aldrich; P0044). After centrifugation at 13,000× rpm for 10 mins to remove cell  
410 debris, protein concentration of each sample was measured using the Bradford assay (Protein  
411 Assay Dye Reagent Concentrate; Bio-Rad). After normalization, extracts were incubated with 2×  
412 TruPAGE™ LDS Sample Buffer (Sigma-Aldrich) at 70 °C for 10 mins. SDS-PAGE gels of  
413 different percentages were used to run protein samples of difference sizes. After transferring  
414 proteins from gels to PVDF membranes (Merck-Millipore) using Trans-Blot Turbo System (Bio-  
415 Rad), membranes were blocked with 5% nonfat dried milk in TBST for 1h, immunoblotted with  
416 antibodies specified in Supplementary Information Table 1. Anti-Rabbit IgG (whole molecule)–  
417 Peroxidase antibody produced in goat (A0545; Merck-Sigma-Aldrich) was used as secondary  
418 antibody following the use of above antibodies. Ponceau S solution (P7170; Sigma-Aldrich) was  
419 used to stain the PVDF membrane for loading control. For RbohD and BIK1, plasma membrane  
420 protein was extracted for immunoblotting (see below).

#### 421 Immunoblotting (co-treatment with ETI)

422 5-week-old est:AvrRps4 leaves were infiltrated with indicated solutions (concentration indicated  
423 in Supplementary Table 3) for indicated time point. Tissues were then collected and snap-frozen.  
424 Proteins were extracted and immunoblotting was performed as stated above. Concentrations of  
425 primary antibodies are specified in Supplementary Information Table 1. Anti-Rabbit IgG (whole  
426 molecule)–Peroxidase antibody produced in goat (A0545; Merck-Sigma-Aldrich) was used as  
427 secondary antibody following the use of above antibodies. Ponceau S solution (P7170; Sigma-  
428 Aldrich) was used to stain the PVDF membrane for loading control. For RbohD and BIK1, plasma  
429 membrane protein was extracted for immunoblotting (see below).

#### 430 Plasma membrane protein extraction

431 Minute™ Plant Plasma Membrane Protein Isolation Kit (Invent Biotechnologies, SM-005-P) was  
432 used to extract total membrane fraction from Arabidopsis samples as instructed. Protein  
433 concentration of the cytosolic fraction from each sample was measured using the Bradford assay  
434 (Protein Assay Dye Reagent Concentrate; Bio-Rad). After normalization, total membrane fractions  
435 were dissolved in 2× TruPAGE™ LDS Sample Buffer (Sigma-Aldrich) at 70 °C for 5 mins (in a

436 minimal volume of 80  $\mu$ l). 6% SDS-PAGE gels were used to run the protein samples. After  
437 transferring proteins from gels to PVDF membranes (Merck-Millipore) using Trans-Blot Turbo  
438 System (Bio-Rad), membranes were blocked with 5% nonfat dried milk in TBST for 1 h,  
439 immunoblotted with either BIK1, pS39-RbohD or pS343-RbohD antibodies kindly provided by  
440 Jian-Min Zhou (Institute of Genetics and Developmental Biology, Chinese Academy of  
441 Sciences)<sup>13</sup>. Concentrations of primary antibodies are specified in Supplementary Information  
442 Table 1. Anti-Rabbit IgG (whole molecule)–Peroxidase antibody produced in goat (A0545;  
443 Merck-Sigma-Aldrich) was used as secondary antibody. Ponceau S solution (P7170; Sigma-  
444 Aldrich) was used to stain the PVDF membrane for loading control.

#### 445 Immunoblotting

446 5-week-old *Arabidopsis thaliana* leaves were treated with indicated solution (concentration  
447 indicated in Supplementary Table 3). Tissues were then collected and snap-frozen. Proteins were  
448 extracted and immunoblotting was performed as stated above. Concentrations of primary  
449 antibodies are specified in Supplementary Information Table 1. Anti-Rabbit IgG (whole  
450 molecule)–Peroxidase antibody produced in goat (A0545; Merck-Sigma-Aldrich) was used as  
451 secondary antibody following the use of above antibodies. Ponceau S solution (P7170; Sigma-  
452 Aldrich) was used to stain the PVDF membrane for loading control.

#### 453 RNA-seq and data analysis

454 Leaves from 5-week-old *Arabidopsis* estradiol-inducible AvrRps4 (est:AvrRps4) or  
455 est:AvrRps4<sup>mut</sup><sup>10</sup> were hand-infiltrated with 50  $\mu$ M estradiol for 0 or 4 h. Samples were collected  
456 and total RNA was isolated with TRI Reagent<sup>®</sup> (T9424; Sigma-Aldrich) and RNA Clean &  
457 Concentrator-25 Kit (R1018; Zymo Research). RNA samples are processed by BGI and libraries  
458 are sequenced with BGISEQ-500 sequencing platform. At least 10 M single-end 50-bp reads are  
459 obtained for each RNA-seq library. Adaptor-trimmed clean reads have been uploaded to the  
460 European Nucleotide Archive (ENA) (accession ID: PRJEB34955). After FastQC, Kallisto was  
461 used to map and quantify RNA-seq reads<sup>39</sup>, and kallisto\_quant output files are submitted to the 3D  
462 RNA-seq tool for statistics and data visualization<sup>40</sup>. P-values for differentially expressed (DE)  
463 genes were generated with Fisher Z-transformation after Student's *t*-test and were adjusted with  
464 Benjamini and Hochberg's (BH) method<sup>40</sup>.



465 Serial dilution to estimate protein abundance

466 Fold changes of BIK1, RbohD and MPK3 protein accumulation upon ETI<sup>AvrRps4</sup> is estimated by  
467 serial dilution. Protein samples of ETI<sup>AvrRps4</sup> at 8 h were diluted 2× (1/2), 4× (1/4), 8× (1/8), 16×  
468 (1/16) and 32× (1/32) in 2× TruPAGE™ LDS Sample Buffer (Sigma-Aldrich). Samples were then  
469 loaded together with protein samples of ETI<sup>AvrRps4</sup> at 0 h and ran on 10% SDS-PAGE gels. After  
470 transferring the proteins from gels to PVDF membranes (Merck-Millipore) using Trans-Blot Turbo  
471 System (Bio-Rad), membranes were blocked with 5% nonfat dried milk in TBST for 1 h,  
472 immunoblotted with antibodies specified in Supplementary Information Table 1. Anti-Rabbit IgG  
473 (whole molecule)–Peroxidase antibody produced in goat (A0545; Merck-Sigma-Aldrich) was  
474 used as secondary antibody. Ponceau S solution (P7170; Sigma-Aldrich) was used to stain the  
475 PVDF membrane for loading control.

476 Cycloheximide and MG132 treatment

477 1-week-old seedlings of est:AvrRps4 Arabidopsis transgenic line were grown in liquid MS  
478 supplemented with 1% sucrose were pre-treated with 50 µM estradiol or mock (DMSO) for 3 h.  
479 After pre-treatment, cycloheximide (CHX; 50 µM), MG132 (10 µM), or combination of CHX and  
480 MG132 were treated to seedlings in addition to estradiol or mock. Seedlings were harvested 2 h,  
481 4 h, and 8 h after inhibitor treatments. Upon protein extraction, protein concentration was measured  
482 using Bradford assay, and protein samples were analyzed by immunoblotting as described above.

483 Enrichment of ribosome

484 Enrichment of ribosome was performed based on previous publications<sup>41,42</sup> with modifications. 5-  
485 week old Arabidopsis leaves of est:AvrRps4 were infiltrated with mock (1% DMSO) or 50 µM est  
486 for 6 h. 0.6 g of leaves were harvested and ground in liquid nitrogen and extracted with 5 ml  
487 extraction buffer (0.2 M Tris-HCl, pH 8.4, 50 mM KCl, 25 mM MgCl<sub>2</sub>, 0.5% or Nonidet P-40, 50  
488 µg/ml cycloheximide, RNase inhibitor (RNasin®, Promega). After centrifugation at 13,000× rpm  
489 for 10 mins, supernatant was loaded onto a 1.6 M sucrose cushion. Samples were ultracentrifuged  
490 at 170,000× g for 16 h. Pellet samples were resuspended in 1 ml DEPC-treated water, and 800 µl  
491 was used for RNA extraction and qPCR analysis and 200 µl for protein extraction as described  
492 above.

493 Bacterial growth assay

494 *Pseudomonas syringae* pv. *tomato* strain DC3000 carrying AvrRps4 or empty vector pVSP61 was  
495 grown on selective King's B (KB) medium plates for 48 h at 28 °C. Bacteria were resuspended  
496 and the concentration was adjusted to 0.001 at OD<sub>600</sub>. Abaxial surfaces of 5-week-old Arabidopsis  
497 leaves were infiltrated with bacterial solution by a 1-ml needleless syringe. For quantification, two  
498 leaf discs per leaf were harvested with a 6-mm diameter cork borer (with disc area of 0.283 cm<sup>2</sup>).  
499 For “day 0”, samples were ground in infiltration buffer (10 mM MgCl<sub>2</sub>) and spotted (10 µl/spot)  
500 on selective KB medium. For “day 3”, samples were ground in infiltration buffer, serially diluted  
501 (into 5, 50, 500, 5,000, and 50,000 times), and spotted (6 µl/spot) on selective KB medium. The  
502 number of colonies (CFU per drop) was calculated, and bacterial growth was represented as CFU  
503 cm<sup>-2</sup> of leaf tissue.

#### 504 HR assay in Arabidopsis

505 *Pseudomonas fluorescens* Pf0-1 engineered with a type III secretion system (Pf0-1 “EtHAn”  
506 strains) expressing effectors, AvrRps4, AvrRps4<sup>KRVY135-138AAAA</sup> (mutant AvrRps4; AvrRps4<sup>mut</sup>)<sup>43</sup>,  
507 or pVSP61 empty vector were grown on selective KB plates for 24 h at 28 °C. Wild-type  
508 *Pseudomonas fluorescens* were grown on KB plates with chloramphenicol for 24 h at 28 °C.  
509 *Pseudomonas syringae* pv. *tomato* strain DC3000 *hrcC*<sup>-</sup> or DC3000 were grown on KB plates with  
510 kanamycin for 48 h at 28 °C. Bacteria were harvested from the plates, resuspended in infiltration  
511 buffer (10 mM MgCl<sub>2</sub>) and the concentration was adjusted to indicated OD<sub>600</sub> (Supplementary  
512 Information Table 3). The abaxial surfaces of 5-week-old Arabidopsis leaves were hand infiltrated  
513 with indicated solution by a 1-ml needleless syringe. Cell death was monitored at indicated time  
514 points after infiltration.

#### 515 Electrolyte leakage assay

516 5-week-old Arabidopsis leaves were infiltrated with indicated solutions (Supplementary  
517 Information Table 3) with a 1-ml needleless syringe. Leaf discs were collected with a 2.4-mm-  
518 diameter cork borer from infiltrated leaves. Discs were dried and washed in deionized water for  
519 1h before being floated on 10 ml deionized water (15 discs per sample, three samples per biological  
520 replicate). Electrolyte leakage was measured as water conductivity with a Pocket Water Quality  
521 Meters (LAQUAtwin-EC-33; Horiba) at the indicated time points.

#### 522 Statistical data analysis

523 Statistical data were analyzed using the R software (<https://www.r-project.org/>), and the data were  
524 plotted using the Origin software. For statistical analysis, all data were tested for homoscedasticity  
525 with Levene's test, and normal distribution with Shapiro-Wilk test, and either parametric one-way  
526 ANOVA analysis followed by Tukey's post-hoc HSD test, or non-parametric Kruskal-Wallis test  
527 followed by Dunn's test were applied for statistical significance. Data points with different letters  
528 indicate significant differences of  $P < 0.01$  for Tukey's HSD test results, and  $P < 0.05$  for Dunn's  
529 test. Data points are plotted onto the graph, and number of samples for each data are indicated in  
530 corresponding figure legends. Three biological replicates were tested, and individual biological  
531 replicates are indicated with different shapes of the data points. qPCR assay results were analyzed  
532 using two-sided Welch's t-test for statistical significance (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.001$ ;  
533 \*\*\*\*,  $P \leq 0.0001$ ; otherwise, not significant) between samples. Detailed information of sample  
534 number, statistical analysis values for all experiments can be found in the Supplementary Table 5.

#### 535 Generation of schematic figures

536 Schematic figures in Fig 2e, 4c, Extended Data Fig 3b, c, 5a, 7d and 10e were created with  
537 BioRender.com.

#### 538 References for Methods

- 539 33. Schwessinger, B. *et al.* Phosphorylation-dependent differential regulation of plant growth, cell  
540 death, and innate immunity by the regulatory receptor-like kinase BAK1. *PLoS Genet.* **7**,  
541 e1002046 (2011).
- 542 34. Asai, S. *et al.* A downy mildew effector evades recognition by polymorphism of expression  
543 and subcellular localization. *Nat. Commun.* **9**, 5192 (2018).
- 544 35. Tornero, P., Chao, R. A., Luthin, W. N., Goff, S. A. & Dangl, J. L. Large-scale structure-  
545 function analysis of the Arabidopsis RPM1 disease resistance protein. *Plant Cell* **14**, 435–450  
546 (2002).
- 547 36. Tsuda, K. *et al.* Dual regulation of gene expression mediated by extended MAPK activation  
548 and salicylic acid contributes to robust innate immunity in Arabidopsis thaliana. *PLoS Genet.*  
549 **9**, e1004015 (2013).
- 550 37. Qi, D. *et al.* Recognition of the protein kinase AVRPPHB SUSCEPTIBLE1 by the disease  
551 resistance protein RESISTANCE TO PSEUDOMONAS SYRINGAE5 is dependent on s-

- 552 acylation and an exposed loop in AVRPPHB SUSCEPTIBLE1. *Plant Physiol.* **164**, 340–351  
553 (2014).
- 554 38. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time  
555 quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**, 402–408 (2001).
- 556 39. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq  
557 quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).
- 558 40. Guo, W. *et al.* 3D RNA-seq - a powerful and flexible tool for rapid and accurate differential  
559 expression and alternative splicing analysis of RNA-seq data for biologists. *BioRxiv* (2019).  
560 doi:10.1101/656686
- 561 41. Cho, H. K., Ahn, C. S., Lee, H.-S., Kim, J.-K. & Pai, H.-S. Pescadillo plays an essential role  
562 in plant cell growth and survival by modulating ribosome biogenesis. *Plant J.* **76**, 393–405  
563 (2013).
- 564 42. Ingole, K. D., Dahale, S. K. & Bhattacharjee, S. Proteomic analysis of SUMO1-SUMOylome  
565 changes during defense elicitation in *Arabidopsis*. *BioRxiv* (2020).  
566 doi:10.1101/2020.08.02.233544
- 567 43. Sohn, K. H., Zhang, Y. & Jones, J. D. G. The *Pseudomonas syringae* effector protein,  
568 AvrRPS4, requires in planta processing and the KRYY domain to function. *Plant J.* **57**, 1079–  
569 1091 (2009).

## 570 **Acknowledgments**

571 We thank Jeffery Dangl, Shuta Asai, Roger Innes, Kenichi Tsuda, Shuqun Zhang, Cyril Zipfel,  
572 Jian-Min Zhou, Albrecht von Arnim, Brian Staskawicz, Cecilia Cheval, Yasuhiro Kadota, Ruby  
573 O'Grady, Maddy Morris, Jack Rhodes and Yuli Ding for providing materials, discussion and  
574 technical support. We also thank Cyril Zipfel, Minhang Yuan, Xiufang Xin and Sheng-Yang He  
575 for critical reading of the manuscript. We thank the Gatsby Foundation (United Kingdom) for  
576 funding to the J.D.G.J. laboratory. B.P.M.N was supported by the Norwich Research Park  
577 Biosciences Doctoral Training Partnership from the Biotechnology and Biological Sciences  
578 Research Council (BBSRC) (grant agreement: BB/M011216/1). H.K.A. was supported by  
579 European Research Council Advanced Grant “ImmunitybyPairDesign” (grant agreement:  
580 669926). P.D. acknowledges support from the European Union’s Horizon 2020 Research and  
581 Innovation Program under Marie Skłodowska-Curie Actions (grant agreement: 656243) and a  
582 Future Leader Fellowship from BBSRC (grant agreement: BB/R012172/1).

583 **Author contributions**

584 B.P.M.N., P.D. and J.D.G.J. conceived and conceptualized the study. B.P.M.N. performed the  
585 ROS assay, DAB staining, callose quantification, gene expression analysis, immunoblotting,  
586 protein serial dilution, RNA-seq, bacterial growth assay, HR assay and electrolyte leakage assay.  
587 B.P.M.N performed plasma membrane protein extraction with assistance from H.K.A.. H.K.A  
588 designed and performed the cycloheximide and MG132 experiment. H.K.A. and B.P.M.N.  
589 performed enrichment of ribosomes. P.D. performed the RNA-seq analyses. H.K.A. performed the  
590 statistical analyses. B.P.M.N. and P.D. wrote the original draft. B.P.M.N., H.K.A., P.D. and  
591 J.D.G.J. reviewed and edited the manuscript.

592 **Competing interest declaration**

593 The authors declare no competing interests.

594 **Data availability**

595 All data in this study are available within the article and Supplementary Information. RNA-seq  
596 data generated from this study are given in Supplementary Table 4. Statistical analyses of this  
597 study are provided in Supplementary Table 5. The original sequence data of RNA-seq that support  
598 the findings of this study have been deposited and made publicly available in the European  
599 Nucleotide Archive (ENA) with the primary accession code “PRJEB34955”. All original gel blots  
600 can be found in the Supplementary Figure 1. Source Data from Fig. 1-4 and Extended Data Fig.  
601 1-9 are provided with the paper.

602 **Correspondence and requests for materials should be addressed to P.D. or J.D.G.J.**

603 **Additional Information**

604 Supplementary Information is available for this paper.

605 **Extended Data Fig. 1 | ETI<sup>AvrRps4</sup> and ETI<sup>AvrRpt2</sup> potentiates PTI responses. (a)** Estradiol pre-  
606 treatment in est:AvrRps4 leads to stronger and prolonged ROS burst compared to mock pre-  
607 treatment.  $n = 40$  leaf disks. **(b)** ROS accumulation over 55 mins in ETI<sup>AvrRps4</sup>-pretreated leaves is  
608 significantly higher than mock-pretreated leaves.  $n = 120$  leaves over 3 independent experiments.  
609 **(c)** Pre-treatment of estradiol in est:AvrRps4 *eds1-2* does not lead to stronger and prolonged ROS  
610 burst compared to mock pre-treatment.  $n = 40$  leaf disks. **(d)** ROS accumulation over 55 mins in

611 ETI<sup>AvrRps4</sup>-pretreated leaves in the *eds1-2* is comparable to mock-pretreated leaves.  $n = 120$  leaves  
612 over 3 independent experiments. **(e)** ROS accumulation of PTI, ETI<sup>AvrRps4</sup> and “PTI + ETI<sup>AvrRps4</sup>”  
613 treated leaves during Phase I (0-60 mins), Phase II (60-300 mins) and Phase III (300-960 mins).  $n$   
614 = 120 leaves over 3 independent experiments.. **(f)** Summary table of ROS accumulation in different  
615 phases. **(g)** “PTI + ETI<sup>AvrRps4</sup>” leads to a stronger *PER4*, *WRKY31* transcript accumulation  
616 compared to PTI or ETI<sup>AvrRps4</sup> alone. *ICS1* transcript is induced upon “PTI + ETI<sup>AvrRps4</sup>” as well as  
617 ETI<sup>AvrRps4</sup> alone. Data points from 3 independent experiments were plotted onto the graphs, with  
618  $\pm$ S.E. for error bars. Two-sided Welch’s t-test was used to analyze significance differences  
619 between PTI + ETI<sup>AvrRps4</sup> and PTI or ETI<sup>AvrRps4</sup> (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P$   
620  $\leq 0.001$ ; otherwise, not significant). Exact P values can be found in Supplementary Table 5. **(h)**  
621 PTI + ETI<sup>AvrRpt2</sup> leads to prolonged ROS production during Phase II.  $n = 40$  leaf disks. **(i)** ROS  
622 accumulation of PTI, ETI<sup>AvrRpt2</sup> and PTI+ETI<sup>AvrRpt2</sup> treated leaves during Phase I, Phase II and  
623 Phase III and in total.  $n = 120$  leaves over 3 independent experiments. **(j)** Summary table of ROS  
624 accumulation in different phases. For **(a)**, **(c)**, **(h)** Solid line represents mean  $\pm$  S.E. (shaded curve)  
625 from one biological replicate. For **(b)**, **(d)**, **(e)**, **(i)**, data points from 3 independent experiments  
626 were analyzed with one-sided Kruskalis-Wallis test followed by post hoc Dunn’s test. Different  
627 letters next to the boxplot indicate significant differences of  $P < 0.05$ . Centre lines represent the  
628 medians; bounds of box indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles; whiskers represent 1.5 $\times$  interquartile  
629 range from 25<sup>th</sup> and 75<sup>th</sup> percentiles. P-values were adjusted using Holm correction, and exact P-  
630 values can be found in Supplementary Table 5. All experiments were repeated at least three times  
631 with similar results.

632 **Extended Data Fig. 2 | ETI<sup>AvrRps4</sup> enhances ROS production triggered by different PAMPs**  
633 **and DAMP. (a-c)** elf18-triggered ROS production in the presence of ETI<sup>AvrRps4</sup> is stronger than  
634 elf18 treatment alone. **(d-f)** pep1-triggered ROS production in the presence of ETI<sup>AvrRps4</sup> is stronger  
635 than pep1 treatment alone. **(g-i)** C10:0-triggered ROS production in the presence of ETI<sup>AvrRps4</sup> is  
636 stronger than C10:0 treatment alone. **(j-l)** nlp20-triggered ROS production in the presence of  
637 ETI<sup>AvrRps4</sup> is stronger than nlp20 treatment alone. **(m-o)** Chitin-triggered ROS production in the  
638 presence of ETI<sup>AvrRps4</sup> is stronger than chitin treatment alone. Shaded curves in **(a)**, **(d)**, **(g)**, **(j)**,  
639 **(m)** represent standard error (S.E.) and solid line represents mean..  $n = 40$  leaf disks. ROS  
640 production in Phase I, Phase II, Phase III and total are shown as boxplots in **(b)**, **(e)**, **(h)**, **(k)** and  
641 **(n)**. Centre lines represent the medians; bounds of box indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles;

642 whiskers represent 1.5× interquartile range from 25<sup>th</sup> and 75<sup>th</sup> percentiles. Data points from 3  
643 independent experiments were analyzed with one-sided Kruskalis-Wallis test followed by post hoc  
644 Dunn’s test. Different letters next to the boxplot indicate significant differences of  $P < 0.05$ .  $n =$   
645 120 leaves over 3 independent experiments. P values were adjusted using Holm correction, and  
646 exact P values can be found in Supplementary Table 5. **(c), (f), (i), (l), (o)** Tabular summary of  
647 total ROS production in different phases upon different PAMPs or DAMP treatments with  
648 ETI<sup>AvrRps4</sup> co-activation. All experiments were repeated at least three times with similar results.

649 **Extended Data Fig. 3 | Protein accumulation of PTI signaling components during ETI. (a)**  
650 PTI signaling pathway. **(b-c)** Schematic representation of “natural infection mimicking” and “ETI  
651 pre-activation” experimental design. ETI<sup>AvrRps4</sup> was activated by estradiol treatment. \* indicates  
652 activated immune system. (red: PTI activation; yellow: ETI activation, blue: PTI and ETI co-  
653 activation). **(d)** Pre-activation of ETI<sup>AvrRps4</sup> leads to accumulation and prolonged phosphorylation  
654 of MPK3 compared to mock pre-treatment. **(e)** Pre-activation of ETI<sup>AvrRps4</sup> leads to accumulation  
655 and prolonged phosphorylation of BIK1 and RbohD (S39 and S343) compared to mock pre-  
656 treatment. Microsomal fractions from each sample were isolated for immunoblotting. Molecular  
657 weight marker (in kDa) is indicated on the left. Ponceau staining (PS) was used as loading control.  
658 **(f)** Transcript induction of corresponding effectors and *ICS1* upon induced expression of *AvrRpm1*  
659 (dex:AvrRpm1), *AvrRpt2* (est:AvrRpt2), *AvrPphB* (est:AvrPphB), *AvrRps4* (est:AvrRps4) and  
660 *AvrRpp4* (est:AvrRpp4). Extracted RNA were analyzed by qPCR and expression level is presented  
661 as relative to *EF1α*. Data points from 3 independent experiments were plotted onto the graphs,  
662 with ±S.E. for error bars.. Two-sided Welch’s t-test was used to analyze significance in differences  
663 of 4 h, 8 h data points from 0h. (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P \leq 0.001$ ;  
664 otherwise, not significant). Exact P-values can be found in Supplementary Table 5. **(g)** Protein  
665 accumulation of BAK1, SOBIR1, BIK1, RbohD, MPK3, MPK6, FLS2, CERK1 and MPK4 upon  
666 ETI activation for 4 h, 8 h in multiple effector inducible lines. 5-week-old leaves of inducible-  
667 AvrRpm1, AvrRpt2, AvrPphB, AvrRps4 and AvrRpp4 lines were infiltrated with 50μM dex (for  
668 dex:AvrRpm1) or 50μM est. Samples were collected at 0, 4 and 8 h post infiltration (hpi) for  
669 protein extraction. Molecular weight marker (in kDa) is indicated on the left. Ponceau staining

670 (PS) were used as loading control. All experiments were repeated at least three times with similar  
671 results.

672 **Extended Data Fig. 4 | Transcript accumulation of PTI signaling components during ETI.**

673 (a) Relative gene expression of *BAK1*, *SOBIR1*, *BIK1*, *RbohD*, *MPK3*, *MPK6*, *FLS2*, *CERK1*,  
674 *MPK4* and *RbohF* relative to *EF1 $\alpha$*  in multiple effector-inducible lines. 5-week-old leaves of  
675 inducible-AvrRpm1, AvrRpt2, AvrPphB, AvrRps4 and AvrRpp4 lines were infiltrated with 50  $\mu$ M  
676 dex (for dex:AvrRpm1) or 50  $\mu$ M est. Samples were collected at 0, 4 and 8 hpi for RNA extraction.  
677 (b) Heatmap of fold-changes ( $\log_2$ FC) of *BAK1*, *SOBIR1*, *BIK1*, *RbohD*, *MPK3*, *MPK6*, *FLS2*,  
678 *CERK1*, *MPK4* and *RbohF* from (a). Gene expression at 4 h and 8 h was normalized to expression  
679 level at 0 h. Red indicates upregulation and blue indicates downregulation. (c) Protein  
680 accumulation of BIK1, RbohD, and MPK3 during ETI<sup>AvrRps4</sup> is abrogated in *eds1-2*. Proteins were  
681 extracted from est:AvrRps4 and est:AvrRps4 *eds1-2* upon est treatment for 0 h, 4 h, and 8 h.  
682 Molecular weight marker (in kDa) is indicated on the left. Ponceau staining (PS) were used as  
683 loading control. (d) Transcript induction of *BIK1*, *RbohD*, and *MPK3* during ETI<sup>AvrRps4</sup> is  
684 abrogated in *eds1-2*. For (a) and (d), extracted RNA were analyzed by qPCR and expression level  
685 is presented as relative to *EF1 $\alpha$* . Data points from 3 independent experiments were plotted onto  
686 the graphs, with  $\pm$ S.E. for error bars. Two-sided Welch's t-test was used to analyze significance in  
687 differences of 4 h, 8 h data points from 0h (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P \leq$   
688 0.001; otherwise, not significant). Exact P-values can be found in Supplementary Table 5. All  
689 experiments were repeated at least three times with similar results.

690 **Extended Data Fig. 5 | Genome-wide gene expression profiling of ETI<sup>AvrRps4</sup>.**

691 (a) Schematic design of RNA-seq analysis. 5-week-old inducible lines of wild-type AvrRps4 (est:AvrRps4) and  
692 mutant AvrRps4 (estradiol-inducible AvrRps4<sup>KRVY135-138AAAA</sup>-expressing line or est:AvrRps4<sup>mut</sup>)  
693 were infiltrated with mock or 50  $\mu$ M est and samples were collected at 0 h, and 4 h. Samples from  
694 three biological replicates were collected for RNA-seq analysis. (b) 2573 differentially expressed  
695 (DE) genes were identified as significant in comparison between est:AvrRps4 treated with  
696 estradiol for 0 h (est:AvrRps4, Est-0h) and est:AvrRps4 treated with est for 4 h (est:AvrRps4, Est-  
697 4h). P values for differentially expressed (DE) genes were generated with Fisher Z-transformation  
698 after Student's *t*-test. DE genes with "Benjamini and Hochberg's (BH) method" false discovery  
699 rate (FDR) two-sided adjusted P-value (adj.pval) < 0.01 are categorized as significant. Heatmap



700 representing the 2573 DE genes during 5 treatments; est:AvrRps4 (Untreated), est:AvrRps4 treated  
701 with est for 0 h (Est-0h), est:AvrRps4 treated with est for 4 h (Est-4h), est:AvrRps4<sup>mut</sup> treated with  
702 est for 0 h (Est-0h) and est:AvrRps4<sup>mut</sup> treated with est for 4 h (Est-4h). Genes that are specifically  
703 upregulated during ETI<sup>AvrRps4</sup> are in cluster 7 and 8. **(c-e)** GO enrichment analysis of genes from  
704 cluster 7 and 8. **(c)** Top three significantly enriched biological process GO-terms in cluster 7 and  
705 8. **(d)** Top four significantly enriched molecular function GO-terms in cluster 7 and 8. **(e)** Top four  
706 significantly enriched cellular component GO-terms in cluster 7 and 8. For details of GO  
707 enrichment analysis refer to Source Data. **(f)** Red (positive log<sub>2</sub>FC (fold change)) represents genes  
708 that are significantly induced and blue (negative log<sub>2</sub>FC) represents genes that are significantly  
709 repressed. BH-FDR two-sided adjusted P-value (adj.pval) < 0.05 is considered as significant.  
710 Gradient of green color indicates significance of the adjusted P-value. For full list of DE genes  
711 refer to Supplementary Table 4.

712 **Extended Data Fig. 6 | Expression dynamics of PTI signaling components during ETI<sup>AvrRps4</sup>.**

713 **(a)** Transcript induction of *SOBIR1*, *BAK1*, *BIK1*, *RbohD*, *MPK3*, *CERK1*, *MPK4*, *MPK6*, *ICSI*,  
714 *PR1* during ETI<sup>AvrRps4</sup> over 24 h. Transcript levels were normalized to *EF1a*. Data points from 3  
715 independent experiments were plotted onto the graphs, with ±S.E. for error bars. Two-sided  
716 Welch's t-test was used to analyze significance in differences of data points from ETI<sup>AvrRps4</sup>-  
717 activated samples compared to untreated (UNT) samples (\*, P ≤ 0.05; \*\*, P ≤ 0.01; \*\*\*, P ≤ 0.005;  
718 \*\*\*\*, P ≤ 0.001; otherwise, not significant). Exact P values can be found in Supplementary Table  
719 5. **(b)** Relative mRNA expression changes of *ICSI* (green) and *PR1* (black) during ETI<sup>AvrRps4</sup>.  
720 Relative expression changes of the corresponding genes to untreated samples (Log<sub>2</sub>FC = 0, dotted  
721 line) are shown. Solid line represents mean ± S.E. (shaded band). **(c)** Heatmap representing fold-  
722 changes (log<sub>2</sub>FC) of transcripts from **(a)**. Gene expression at indicated time points are relative  
723 value to untreated samples. Red indicates upregulation and blue indicates downregulation. **(d)**  
724 Protein accumulation of PR1 at different time points. Ponceau staining of western blots from Fig.  
725 3b are also shown. **(e)** Serial dilution to estimate protein accumulation of BIK1, RbohD and MPK3  
726 at 8h after ETI<sup>AvrRps4</sup> activation compared to 0 h. Red asterisk indicates approximate fold  
727 differences between 0 h and 8 h. **(f)** 5-week old Arabidopsis rosette leaves of est:AvrRps4 were  
728 treated with *hrcC*, est, or "*hrcC* + est" for indicated timepoints and both RNA and proteins were  
729 extracted. Extracted RNA were analyzed by qPCR and expression level is presented as relative to  
730 *EF1a*. Data points from 3 independent experiments were plotted onto the graphs, with ±S.E. for

731 error bars (PTI: red; ETI<sup>AvrRps4</sup>: yellow; “PTI + ETI<sup>AvrRps4</sup>”: blue). Two-sided Welch’s t-test was  
732 used to analyze significance in differences of 4h, 8h data points from 0h (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ;  
733 \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P \leq 0.001$ ; otherwise, not significant). Exact P-values can be found in  
734 Supplementary Table 5. For (d), (e), (f), Ponceau staining (PS) was used as loading control.  
735 Molecular weight marker (in kDa) is indicated on the left. All experiments were repeated at least  
736 three times with similar results.

737 **Extended Data Fig. 7 | Multiple mechanisms are involved in the upregulation of PTI signaling**  
738 **components during ETI<sup>AvrRps4</sup>.** (a) Relative gene expression of *ICS1*, *BIK1*, *RbohD*, *MPK3* and  
739 *MPK6* in seedlings pre-activated with ETI<sup>AvrRps4</sup> for 3 h prior to treatment with cycloheximide  
740 (CHX) and MG132. Data points from 3 independent experiments were plotted onto the graphs,  
741 with  $\pm$ S.E. for error bars.. Two-sided Welch’s t-test was used to analyze significance in differences  
742 at 3h compared to 0h (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P \leq 0.001$ ; otherwise, not  
743 significant). Exact P values can be found in Supplementary Table 5. (b, c) Protein accumulation  
744 of MPK3, RbohD, BIK1, MPK6, Actin in seedlings pre-treated with Mock (DMSO) for 3 h (b),  
745 and RPS4-HA, FLS2, and BAK1 (c) in seedlings pre-treated with Mock or est, subsequently  
746 treated with CHX (50  $\mu$ M), MG132 (10  $\mu$ M), or both for indicated times (2 h, 4 h, 8 h). Actin was  
747 used as loading control. Ponceau staining (PS) of corresponding blots are shown below. For FLS2  
748 and Actin, as well as BAK1 and BIK1, immunoblot was performed with membranes cut in half  
749 (above 70 kDa for FLS2, BAK1, respectively, below 70 kDa for Actin and BIK1 immunoblot,  
750 respectively). Therefore, Ponceau staining (PS) for FLS2 and Actin, BAK1 and BIK1, respectively,  
751 are identical. (d) Schematic representation of ribosome enrichment. (e-f) Ribosome was enriched,  
752 and (e) total extract (T), supernatant (S), and ribosomal pellet (P) samples were blotted with RPS6  
753 and RPL10 antibody. For (b), (c) and (e), Ponceau staining (PS) was used as loading control.  
754 Molecular weight marker (in kDa) is indicated on the left. (f) RNA extracted from total extract  
755 (Total RNA), and ribosomal pellet (Ribosome RNA) from mock and est-treated est:AvrRps4  
756 samples were loaded on an agarose gel. 28S and 18S rRNA are indicated. (g) Relative expression  
757 of *ICS1*, *SOBIR1*, *BAK1*, *BIK1*, *RbohD* and *MPK3* to *EF1 $\alpha$*  from total RNA (Total) and ribosomal  
758 pellet (Ribosomal). Data points from 3 independent experiments were plotted onto the graphs,  
759 with  $\pm$ S.E. for error bars. Two-sided Welch’s t-test was used to analyze significance in differences  
760 of 6 h compared to 0 h (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P \leq 0.001$ ; otherwise, not  
761 significant). Exact P-values can be found in Supplementary Table 5. (h) Ratio of ribosomal RNA

762 to total RNA (relative to *EF1α*) of *ICSI*, *SOBIR1*, *BAK1*, *BIK1*, *RbohD* and *MPK3* in mock and  
763 ETI samples. Values are calculated from the transcripts retained in the ribosomal samples over  
764 total samples. Data points from 3 independent experiments were plotted onto the graphs, with  
765  $\pm$ S.E. for error bars. All experiments were repeated at least three times with similar results. Two-  
766 sided Welch's t-test was used to analyze significance in differences of the translation efficiency  
767 (T.E.) between Mock and ETI-treated samples (\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$ ; \*\*\*,  $P \leq 0.005$ ; \*\*\*\*,  $P$   
768  $\leq 0.001$ ; otherwise, not significant). Exact P-values can be found in Supplementary Table 5.

769 **Extended Data Fig. 8 | ETI functions through PTI.** (a) 5-week-old leaves of *est:AvrRps4* were  
770 infiltrated with *Pst* strain DC3000 *hrcC*<sup>-</sup> (*Pst hrcC*<sup>-</sup>; triggers PTI), *Pst* DC3000 (*Pst*; triggers “PTI  
771 + ETS”), or “50  $\mu$ M *est* + *Pst hrcC*”(triggers “PTI - ETS + ETI<sup>AvrRps4</sup>”), and samples were  
772 collected at the indicated time points for protein extraction and immunoblotting. PTI leads to  
773 activation of MAPKs and accumulation of BIK1 and RbohD (red). *Pst* secretes effectors to block  
774 PTI (green). Co-activation of PTI and ETI<sup>AvrRps4</sup> leads to stronger accumulation of MPK3, BIK1  
775 and RbohD compared to PTI (blue). MAPKs activation is also prolonged during “PTI +  
776 ETI<sup>AvrRps4</sup>”. (b) Updated version of the “zig-zag-zig” model. (c) Col-0, *rps4-2 rps4b-2* and *bak1-  
777 5 bkk1-1* were infected with *Pst* DC3000 carrying AvrRps4 (red) or empty vector (grey). Bacterial  
778 growth at 0 dpi as measured.  $n = 12$  leaves. (d) Col-0, *rps4-2 rps4b-2* and *fls2 efr* were infected  
779 with *Pst* DC3000 carrying AvrRps4 (red) or empty vector (grey). Both *rps4-2 rps4b-2* (No ETI)  
780 and *fls2 efr* (PTI-reduced) are insufficient to provide resistance against *Pst* DC3000:AvrRps4  
781 compared to Col-0 (“PTI + ETI”). Day 0:  $n = 12$  leaves; day 3:  $n = 18$  leaves. For (c), (d), data  
782 points were analyzed by one-way ANOVA followed by post hoc Tukey's HSD test. Data points  
783 with different letters indicate significant differences of  $P < 0.01$ . (e) flg22-induced ROS burst is  
784 not affected in *rps4-2 rps4b-2*. Shaded curve represents standard error (S.E.) and solid line  
785 represents average value from 24 leaves in each treatment during  $n = 24$  leaves. (f) flg22-induced  
786 ROS production over 55 mins in Col-0 and *rps4-2 rps4b-2*. Data points from 3 biological replicates  
787 were analyzed with one-sided Kruskal-Wallis test followed by post hoc Dunn's test. Data points  
788 with different letters indicate significant differences of  $P < 0.05$ .  $n = 72$  leaves over 3 independent  
789 experiments. (g) flg22-induced MPK phosphorylation is not affected in *rps4-2 rps4b-2*. Upon  
790 flg22 treatment, samples were taken at indicated time points for immunoblotting. For (a), (g),  
791 Ponceau staining (PS) was used as loading control. Molecular weight marker (in kDa) is indicated  
792 on the left. All experiments were repeated at least three times with similar results. For (c), (d), (f),

793 centre lines represent the medians; bounds of box indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles; whiskers  
794 represent 1.5× interquartile range from 25<sup>th</sup> and 75<sup>th</sup> percentiles. Exact P-values can be found in  
795 Supplementary Table 5.

796 **Extended Data Fig. 9 | Potentiation of ETI<sup>AvrRps4</sup>-induced HR by PTI. (a)** Pf0-1:AvrRps4 leads  
797 to macroscopic HR in est:AvrRps4 leaves. Both PTI (Pf0-1:AvrRps4<sup>mut</sup>) or ETI<sup>AvrRps4</sup> (est) does  
798 not lead to macroscopic HR. Coactivation of PTI and ETI<sup>AvrRps4</sup> (est + Pf0-1:AvrRps4<sup>mut</sup>) leads to  
799 macroscopic HR. The numbers indicate number of leaves displaying HR of the total number of  
800 leaves infiltrated. *n* = 18 leaves. **(b)** Est:AvrRps4 leaves were hand-infiltrated with indicated  
801 solutions and electrolyte leakage was measured over 48hpi. Combination of “PTI + ETI<sup>AvrRps4</sup>”  
802 (blue dots, “est + Pf0-1:AvrRps4<sup>mut</sup>”) leads to stronger electrolyte leakage compared to ETI<sup>AvrRps4</sup>  
803 (est) or PTI (Pf0-1:AvrRps4<sup>mut</sup>) alone. Pf0-1:AvrRps4 (green) acts as a positive control. Data  
804 points from 3 biological replicates were analyzed with one-way ANOVA followed by post hoc  
805 Tukey’s HSD test. Data point from each biological replicate is indicated with different shapes.  
806 Data points with different letters indicate *P* < 0.01. *n* = 9 data points; each represents data from 15  
807 leaf discs. Exact P-values can be found in Supplementary Table 5. **(c)** PTI induced by flg22, elf18,  
808 pep1, C10:0, nlp20 or chitin does not lead to macroscopic HR. Coactivation of PTI (trigger by  
809 these PAMPs or DAMP) with ETI<sup>AvrRps4</sup> leads to macroscopic HR. The numbers indicate number  
810 of leaves displaying HR of the total number of leaves infiltrated. *n* = 18 leaves. **(d)** 5-week-old  
811 inducible AvrRpm1 (dex:AvrRpm1), AvrRpt2 (est:AvrRpt2), AvrPphB (est:AvrPphB), AvrRps4  
812 (est:AvrRps4) and AvrRpp4 (est:AvrRpp4) Arabidopsis leaves were infiltrated with either dex (for  
813 dex:AvrRpm1 only) or est. All pictures were taken at 3 dpi. The numbers indicate the number of  
814 leaves displaying HR of the total number of leaves infiltrated. *n* = 18 leaves. **(e)** Combination of  
815 “PTI + ETI” leads to stronger macroscopic HR in inducible-AvrRpm1, AvrRpt2, AvrPphB and  
816 AvrRpp4 Arabidopsis lines. All pictures were taken 3 dpi. The numbers indicate number of leaves  
817 displaying HR of the total number of leaves infiltrated. *n* = 18 leaves. All experiments were  
818 repeated at least three times with similar results.

819 **Extended Data Fig. 10 | MAPKs and NADPH oxidases are involved in HR induced by PTI +**  
820 **ETI. (a)** MPK phosphorylation during ETI triggered by multiple effectors. Seedlings of  
821 dex:AvrRpm1, est:AvrRpt2, est:AvrPphB and est:AvrRpp4 lines were soaked in dex or est,  
822 solution respectively for indicated time points (dark yellow). Untreated (UNT) seedlings were used

823 as negative control, seedlings treated with 100 nM flg22 for 15 min (red, flg22) were used as  
824 positive control. **(b)** RbohD phosphorylation during ETI triggered by multiple effectors. Seedlings  
825 of dex:AvrRpm1, est:AvrRpt2, est:AvrPphB and est:AvrRpp4 were soaked in either mock (black),  
826 dex or est solution (dark yellow) for 6 h. Microsomal fraction from seedlings were isolated for  
827 immunoblotting. For **(a)**, **(b)**, Ponceau staining (PS) was used as loading control. Molecular weight  
828 marker (in kDa) is indicated on the left. **(c)** MPK6SR#58 (*mpk3 mpk6* P<sub>MPK6</sub>:MPK6<sup>YG</sup>) is a  
829 conditional *mpk3 mpk6* double mutant. MPK6<sup>YG</sup> has a larger ATP binding pocket than MPK6<sup>WT</sup>  
830 and is sensitive to the inhibitor 1-Naphthyl-PP1 (NA-PP1, ATP analog). Pre-treatment with NA-  
831 PP1 inhibits MPK6<sup>YG</sup> and temporarily generates a *mpk3 mpk6* double mutant. Both Col-0 and  
832 MPK6SR#58 leaves were pre-infiltrated with either 1% DMSO (mock) or 10 μM NA-PP1. After  
833 3 h, these leaves were infiltrated with either Pf0-1:empty vector (triggers PTI) or Pf0-1:AvrRps4  
834 (triggers “PTI + ETI<sup>AvrRps4</sup>”). With mock pre-treatment, Pf0-1:AvrRps4 infiltration leads to  
835 macroscopic HR in both Col-0 and MPK6SR#58. NA-PP1 pre-treatment attenuates HR caused by  
836 Pf0-1:AvrRps4 only in the MPK6SR#58 line. All pictures were taken at 1 dpi. The numbers  
837 indicate number of leaves displaying HR of the total number of leaves infiltrated. *n* = 18 leaves.  
838 **(d)** Col-0 and *rbohD rbohF* leaves were infiltrated with either Pf0-1:empty vector (triggers PTI) or  
839 Pf0-1:AvrRps4 (triggers “PTI + ETI<sup>AvrRps4</sup>”) at varying OD<sub>600</sub>. With OD<sub>600</sub> = 0.025, Pf0-  
840 1:AvrRps4 infiltration leads to less macroscopic HR in *rbohD rbohF*. All pictures were taken 1 dpi.  
841 The numbers indicate number of leaves displaying HR of the total number of leaves infiltrated. *n*  
842 = 18 leaves. All experiments were repeated at least three times with similar results. **(e) Model:**  
843 Upon ligand detection by PRRs, PTI leads to activation of BIK1, RbohD and MAPKs. Activation  
844 of an NLR (ETI without PTI) elevates accumulation of PTI signaling components. Co-activation  
845 of both PTI and ETI elevates accumulation and enhances activation of multiple PTI signaling  
846 components, enabling a stronger immune response.